Epidiolex and Epilepsy - big changes for medical marijuana | Datamonitor Healthcare

With the FDA’s landmark approval of Epidiolex, a cannabidiol used to treat rare, severe pediatric epilepsies, the only obstacle to the legal sale of the drug is DEA reclassification of cannabidiol (CBD). With reclassification likely in the next 90 days, what does it mean for the epilepsy market, as well as the wider market for CBD?

Download Potential of First-in-Class Epidiolex for Epilepsy and its Significance in the Advent of Medical Marijuana and Discover:

Epidiolex's potential as a first-in-class drug in the epilepsy market and the first FDA-approved drug for Dravet syndrome

Regulatory repercussions in the form of drug scheduling following the first cannabis plant-derived drug to receive FDA approval

Biomedtracker analyses, including change to Likelihood of Approval (LOA)

In-depth analysis of historical trends and the current global status of cannabinoid drug development for targeted indications

Evaluation of important issues pertinent to medicinal cannabinoid development and its potential to successfully address the opioid crisis

Download whitepaper

Next steps

Request a Demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Speak to Sales

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact Sales

Client Services

US Toll-Free : +1 888 670 8900
US Toll : +1 212-600-3520
UK & Europe : +44 (0) 208 052 0700

Contact Customer Services

Pharma Report Store

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now

Epidiolex and Epilepsy - big changes for medical marijuana

Next steps